ATOS Stock Summary and Trading Ideas (Atossa Therapeutics | NASDAQ:ATOS)

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Atossa Therapeutics trades on the NASDAQ stock market under the symbol ATOS.

As of June 12, 2026, ATOS stock price declined to $2.46 with 620,495 million shares trading.

ATOS has a beta of 1.52, meaning it tends to be more sensitive to market movements. ATOS has a correlation of 0.04 to the broad based SPY ETF.

ATOS has a market cap of $21.18 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ATOS traded as high as $34.65 and as low as $2.45.

The top ETF exchange traded funds that ATOS belongs to (by Net Assets): VTI, VXF, DFMC.

ATOS has underperformed the market in the last year with a price return of -81.0% while the SPY ETF gained +24.1%. ATOS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -51.3% and -53.0%, respectively, while the SPY returned +11.6% and -1.9%, respectively.

ATOS support price is $2.47 and resistance is $2.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATOS shares will trade within this expected range on the day.